Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation.

Abbas Shakoori, Andrei Ougolkov, Zhi Wei Yu, Bin Zhang, Mohammad H Modarressi, Daniel D Billadeau, Masayoshi Mai, Yutaka Takahashi, Toshinari Minamoto

Index: Biochem. Biophys. Res. Commun. 334(4) , 1365-73, (2005)

Full Text: HTML

Abstract

Glycogen synthase kinase 3beta (GSK3beta) reportedly has opposing roles, repressing Wnt/beta-catenin signaling on the one hand but maintaining cell survival and proliferation through the NF-kappaB pathway on the other. The present investigation was undertaken to clarify the roles of GSK3beta in human cancer. In colon cancer cell lines and colorectal cancer patients, levels of GSK3beta expression and amounts of its active form were higher in tumor cells than in their normal counterparts; these findings were independent of nuclear accumulation of beta-catenin oncoprotein in the tumor cells. Inhibition of GSK3beta activity by phosphorylation was defective in colorectal cancers but preserved in non-neoplastic cells and tissues. Strikingly, inhibition of GSK3beta activity by chemical inhibitors and its expression by RNA interference targeting GSK3beta induced apoptosis and attenuated proliferation of colon cancer cells in vitro. Our findings demonstrate an unrecognized role of GSK3beta in tumor cell survival and proliferation other than its predicted role as a tumor suppressor, and warrant proposing this kinase as a potential therapeutic target in colorectal cancer.